1. Home
  2. VHUB vs NSRX Comparison

VHUB vs NSRX Comparison

Compare VHUB & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VenHub Global Inc. Common Stock

VHUB

VenHub Global Inc. Common Stock

N/A

Current Price

$0.19

Market Cap

36.0M

Sector

N/A

ML Signal

N/A

Logo Nasus Pharma Ltd. Ordinary Shares

NSRX

Nasus Pharma Ltd. Ordinary Shares

N/A

Current Price

$2.60

Market Cap

37.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
VHUB
NSRX
Founded
2000
2019
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.0M
37.1M
IPO Year
2025
2024

Fundamental Metrics

Financial Performance
Metric
VHUB
NSRX
Price
$0.19
$2.60
Analyst Decision
Buy
Analyst Count
0
3
Target Price
N/A
★ $16.50
AVG Volume (30 Days)
★ 129.1K
11.6K
Earning Date
11-16-2026
08-17-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $864,450.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$1.98
52 Week High
$15.34
$9.50

Technical Indicators

Market Signals
Indicator
VHUB
NSRX
Relative Strength Index (RSI) 23.74 31.72
Support Level N/A $2.41
Resistance Level $0.29 $3.61
Average True Range (ATR) 0.03 0.20
MACD 0.01 -0.03
Stochastic Oscillator 2.29 4.52

Price Performance

Historical Comparison
VHUB
NSRX

About VHUB VenHub Global Inc. Common Stock

Venhub Global Inc is engaged in designing and building autonomous Smart Stores that operate 24/7 without on-site staff. Each store combines robotic automation, real-time inventory tracking, and mobile-based checkout to provide secure, convenient retail access, and is offered as an integrated retail solution to store operators.

About NSRX Nasus Pharma Ltd. Ordinary Shares

Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.

Share on Social Networks: